Blogs
In today’s fast-moving drug development landscape, bioanalytical continuity and end-to-end support aren’t just conveniences, they’re competitive advantages. Sponsors navigating complex modalities like gene therapies, ADCs, oligonucleotides, and biologics need a partner who can keep pace with aggressive timelines, shifting priorities, and evolving regulatory expectations. Why Continuity Matters in…
webinars
Biomarkers can move a program forward fast. Or slow it down with rework. Biomarkers shape decisions from discovery through late-stage clinical trials. But the wrong assay plan can waste time, budget and samples. In this KCAS Bio roundtable, we share practical ways to align context of use,…
Blogs
At KCAS Bio, we supported a therapeutic monoclonal antibody for advanced solid tumors from non-human primate (NHP) toxicology through first-in-human (FIH) dose escalation into phase 2 expansion. This project combined receptor occupancy assays (ROA) by flow cytometry for cell-surface binding on monocytes, immunophenotyping (IPT) for activation markers,…
Blogs
Developing a robust Pharmacokinetic (PK) assay for biotherapeutics often presents unforeseen biological hurdles. Occasionally, a traditional Ligand Binding Assay (LBA) may yield inconsistent data. In this particular case, the LBA assay was not reliably detecting drug in the matrix, potentially indicating some matrix stability issue during method development. In…
Blogs
What Are Ligand Binding Assays (LBAs)? Ligand binding assays (LBAs) have been our core activity for decades. LBAs are commonly used to measure interactions between two proteins, a ligand and its receptor, a monoclonal antibody (mAb) and its target, or a biologic and Anti-Drug Antibodies (ADA). Applications of…
Blogs
In a bioanalytical CRO, method development is a critical step to ensure reliable and meaningful data that meets the client’s requirements. At our KCAS Bio – Lyon site, our method development team specializes in designing and optimizing ligand-binding assay (LBA) methods tailored to our clients’ specific objectives.
Blogs
What is immunogenicity? Immunogenicity refers to the ability of a substance, such as a New Biological Entity (NBE) or a vaccine, to provoke an immune response when administered in the body. The recognition of the substance as foreign triggers an immune response, which involves the production of antibodies and the…
October 7
- October 10
KCAS Bio will be participating in the Immunogenicity & Bioassay Summit 2025, taking place October 7-10 in Alexandria, VA. This annual summit, hosted by the Cambridge Healthtech Institute, brings together leaders in immunogenicity assessment, bioassay development, and translational science to explore emerging strategies in drug development. With focused…
Blogs
Remember that childhood excitement the night before Christmas? Too excited to sleep, knowing something you wished for was finally within reach? That’s exactly the spirit fueling our teams in Lyon as we approach the end of June. We’re eagerly awaiting the arrival of a powerful new platform…
Posters & Papers
Discover in this poster presented by Jessica Pham at WRIB 2025 on the “Development and Optimization of a Quantitative Assay for an Investigational Anti-Malarial Monoclonal Antibody Drug Candidate in Human Whole Blood Using Volumetric Absorptive Microsampling (VAMS)”. If you have any questions about these services or any others…
Blogs
Initially developed to assess the frequency of circulating antigen-specific Antibody-Secreting Cells (ASC), ELISpot has become a vital tool for quantifying antigen-reactive T-cells by measuring secreted immune mediators such as cytokines or key molecules involved in cell-mediated cytotoxicity. Compared to other assays for monitoring cell-mediated immunity (CMI), such as…
Blogs
ADCs represent a promising class of targeted therapies, and understanding the intricacies of their analysis is crucial for their successful development. In this blog, we address common questions to guide you through the various considerations involved in ADC research and testing. We will cover key topics related to…